Inhalable Levofloxacin Liposomes Complemented with Lysozyme for Treatment of Pulmonary Infection in Rats: Effective Antimicrobial and Antibiofilm Strategy
- 74 Downloads
Treatment of bacterial infections becomes increasingly complicated due to increasing bacterial resistance and difficulty in developing new antimicrobial agents. Emphasis should be laid on improvising the existing treatment modalities. We studied the improved antimicrobial and antibiofilm activity of levofloxacin (LFX) and lysozyme (LYS) in microbiological studies. LFX at sub-minimum inhibitory concentration with LYS eradicated > 85% of preformed biofilm. LFX was actively loaded into the liposomes using pH gradient method and was spray-dried with LYS solution. Percent entrapment of LFX in liposome was > 80% and prolonged cumulative release of 85% LFX at the end of 12 h. In vitro lung deposition study and solid-state characterization for spray dried LFX liposome in combination with LYS (LFX liposome-LYS) was performed. Co-spray dried product had mass median aerodynamic diameter ranging < 5 μm. In pharmacodynamic study, Staphylococcus aureus infected rats were treated with LFX liposome-LYS. Lungs, bronchoalveolar lavage fluid (BALF), and nasal fluid were evaluated for microbial burden. Expression of cytokine levels in BALF and serum were also studied by ELISA. In addition, mRNA expression for lung inflammatory mediators and lung myeloperoxidase activity were carried out. Further, lungs and histological changes were observed grossly. Untreated infected rat lungs demonstrated higher mRNA expression for inflammatory markers, cytokine levels, and microbial load compared to vehicle control. Conversely, LFX liposome-LYS significantly abated these adverse repercussions. Histology findings were also in agreement of above. Acute toxicity study revealed safeness of LFX liposome-LYS. Our findings confirm LFX liposome-LYS exhibited prolonged, improved antibiofilm and antimicrobial efficacy in treating S. aureus infection.
KEY WORDSbiofilm antibiotic enzyme Staphylococcus aureus liposome
This research work was supported by Indian Council of Medical Research (ICMR), File No. AMR/4/2011- ECD-I, New Delhi, India.
Compliance with Ethical Standards
Protocol of in vivo study was approved by the Institution Animal Ethics Committee Bombay College of Pharmacy and carried out in accordance with the guidelines of Committee for the Purpose and Supervision of Animal Experiments.
- 1.Lister JL, Horswill AR. Staphylococcus aureus biofilms: recent developments in biofilm dispersal. Front Cell Infect Microbiol. 2014;4(178):1–9.Google Scholar
- 4.Zakaria AS, Melake NA, Baky NA, El Rasheed NM, Ibrahim NH. In vitro and in vivo studies of antibacterial effect of ceftriaxone moxifloxacin combination against methicillin resistant Staphylococcus aureus biofilms formed on biomedical implants. Afr J Microbiol Res. 2012;6(25):5399–409.Google Scholar
- 7.Estela CRL, Alejandro PR. Biofilms: a survival and resistance mechanism of microorganisms. In: Pana M, editors. Antibiotic resistant bacteria—a continuous challenge in the new millennium. InTech; 2012. ISBN: 978–953–51-0472-8.Google Scholar
- 15.Penta J, Jannu KK, Musthyala R. Antimicrobial studies of selected antibiotics and their combination with enzymes. Int J Pharm Pharm Sci. 2010;2(3):43–4.Google Scholar
- 21.Gao X, Yao G, Guo N, An F, Guo X. A simple and rapid high performance liquid chromatography method to determine levofloxacin in human plasma and its use in a bioequivalence study. Drug Discover Ther. 2007;1(2):136–40.Google Scholar
- 22.Aguilar MI. HPLC of peptides and proteins. vol. 251. New York: Springer; 2004. p. 3–8.Google Scholar
- 25.Pathak P, Dhawan V, Magarkar A, Danne R, Govindarajan S, Ghosh S, et al. Design of cholesterol arabinogalactan anchored liposomes for asialoglycoprotein receptor mediated targeting to hepatocellular carcinoma: in silico modeling, in vitro and in vivo evaluation. Int J Pharm. 2016;509(1):149–58.CrossRefPubMedGoogle Scholar
- 27.Marier JF, Lavigne J, Ducharme MP. Pharmacokinetics and efficacies of liposomal and conventional formulations of tobramycin after intratracheal administration in rats with pulmonary Burkholderia cepacia infection. Antimicrob Agents Chemother. 2002;46(12):3776–81.CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Omri A, Beaulac C, Bouhajib M, Montplaisir S, Sharkawi M, Lagace J. Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1994;38(5):1090–5.CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Naikwade SR, Bajaj AN, Gurav P, Gatne MM, Soni PS. Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study. AAPS PharmSciTech. 2009;10(3):993–1012.CrossRefPubMedPubMedCentralGoogle Scholar
- 42.Feng X, Maze M, Koch LG, Britton SL, Hellman J. Exaggerated acute lung injury and impaired antibacterial defenses during Staphylococcus aureus infection in rats with the metabolic syndrome. PLoS One. 10(5):e0126906. https://doi.org/10.1371/journal.pone.0126906.